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IfflroducliOIl 
1.1 General Matter 
The technology and research revolution has provided many areas of science and industry with tools 
for more extensive and efficient operation. Nowhere is this phenomenon more evident than for new 
drug discovery and development in the pharmaceutical industry. Exploring the relationship between 
the structure of a molecule and its various biological and biochemical properties is the basis of drug 
discovery. Modern approaches to this field of study employ a combination of techniques. These 
include tests based on combinatorial chemistry and high-throughput (HT) screening as well as 
rational phannaceutical design based on geometric and chemical characteri stics of molecule-
molecule interactions. Furthermore. understanding and optimising factors such as the effect of a 
compound on the body and the effect of the body on a compound are essential in developing a new 
drug. 
The main bottleneck in drug discovery is the identification of new chemical entities (NCEs) to be 
used for drug leads. The 1990s saw development of new automated tools for drug discovery 
including combinatorial chem istry and high-throughput screening. These lools have led to the 
increased discovery of new drug lead compounds each of which in tum require pharmacological 
and phannacokinetic lesting. Moreover. substantial increases in computing po\\·er as well as 
development of robust software has given scient ists the opportunity to undertake significant 
research projects from their own desktops. Consequemly. data analysis. data mining. and 
information manipulation have al l benefited and progressed considerably. 
Software programs have been developed for a wide range of fields such as quantitative structure-
activity relationship (QSAR) studies, pharmacophore elucidation. molecular modeling. drug-
receptor interactions and iff vim simu lations. Newer techniques have been innuenced by what is 
termed "soft computing" which aims to accommodate the imprecision and uncertainty inherent in 
the real world [Zadeh. 1996]. Soft computing draws on the model of the human brain and derives 
mainly from artificial intelligence (AI) sources including genetic algorithm (GA). fuzzy logic, and 
artificial neural network (ANN) approaches [Maddalena. 1998]. Other less common techniques 
include cellular automata. fractals and chaos theory. ANNs are aparticularly useful modeling tools 
for nonlinear systems. Although not as common in the pharmaceutical industry as conventional 
modeling and mathematical techniques. soft computing has been successful in a number of fields in 
the industry. 
In particular. soft computing has been useful in the development of quantitative structure-activity 
relationship and quant itative structure-property relationship (QSPR) models. General methods 
involve correlation of physicochemical descriptors of chemical compounds with either an activity or 
property value. Classically. one or two descriptors such as octanol/water partition coefficients and 
molar refractivity are experimentally determined for a group of congeneric compounds (Hansch et 
aL 1995]. These experimental descriptor values are then related to selected biological activity. The 
result is a mathematical model which describes the contribution of the descriptors to the activity. 
Once a predictive model has been built. numerous new pOiential-drug molecules which are 
chemically si milar to those of the benchmark dat!lset can then be screened from large databases. 
These molecules are all evaluated for their biological propenies based on the predictive model 
developed. The aim is to target a few novel molecules with potentially allractive pharmaceutical 
properties that can then be tested further in the traditional way in the laboratory. Effective data 
mining techniques are vi tal to extract the information necessary to select these novel molecules. 
Such models have used both whole molecule descriptors and descriptors for individual substitution 
positions and functional groups on structurally related compounds. Thus. for a single study there 
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may be a large number of potential descriptors for correlation with only a single target activity or 
property. Not all descriptors are useful so selection of meaningful descriptors is crucial for 
successfu l model development. 
Recently. theoretical descriptors generated only from the molecular structure of a compound have 
become popular. Over a thousand of these descriptors have been defined to date although not all are 
entirely useful [Balaban & Ivanciuc. 1999]. Many of these descriptors have been successfully 
correlated with parameters such as boiling points of alkanes [Cherqaoui & Villemin. 1994], aqueous 
solubility [Huuskonen et al.. I 997}. binding affinities [Beck et al.. 1996], and analgesic properties 
(Galvez et aL 1994b]. 
Similarly, quantitative structure-pharmacokinetic relationship (QSPkR) models have also been 
constructed to correlate drug stuctures and their pharmacokinetic parameters [Seydel & Schaper, 
1981 ; Hinderl ing et al.. 1984a; Fouchecourt et al., 2001; Agatonovic-Kustrin et aI. , 2008]. 
However, QSPkRs are not as common in the literature as other QSPRs are. This has largely been 
attributed to the complex factors involved in some pharmacokinetic parameters such as hepatic 
metabolism and elimination half life, as well as the time dependency of drug concentration ill vivo 
[Mayer & van de Waterbeemd, 1985]. 
The development of predictive QS PkR models are of increasing interest to the pharmaceutical 
industry since it would allow valuable information to be gained very early during the drug 
discover/development process. Should successful models be based on structure alone then 
predictions could be made for theoretical chemical structures during screening before they are even 
synthesised . Additionally, knowledge of human phannacokinetics prior to clinical trials would 
enable decisions to be made regarding viability of potential drugs for continued development. This 
would impart another substantial time- and cost-saving benefit. 
There are three essential components invo lved in structure-pharmacokinetic modeling; I) 
acquisition of pharmacokinetic data; 2) generation of theoretical molecular descriptors; and 3) 
model construction. It is difficult to gather consistent pharmacokinetic data from the literature since 
util isation of different sou rces inevitably leads to increased variability amongst the data. There is 
also a huge variety of molecular descriptors and. not surprisingly, different authors rarely use the 
same descriptors. Given that this modeling technique is data-driven , the nature and meaning of 
descriptors selected in models is also very important. 
The remainder of this introduction will deal with the relevant aspects of drug discovery and 
development, pharmacokinetics, pharmakokinetic modeling techniques, available descriptors. and a 
review of current QSPkR modeling. 
1.1.1 Objectives 
The broad aim of this work was to develop predictive QSPkR models using ANNs. Specific 
objectives were to; 
• Identify various theoretical descriptors generated from molecular structure and examine 
their relevance to QS PkR studies. 
• Investigate both selection of descriptors and effects of ANN architecture on QSPkR model 
performance. 
• Explore relationships of theoretical descriptors with different pharmacokinetic parameters. 
• Investigate the viabitity of multiple. simultaneous pharmacokinetic parameter prediction. 
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• Develop predictive QSPkR models fo r both structurally related and structurally unrelated 
sets of drugs. 
• Examine models with both theoretical and experimentally-derived descriptors. 
1.2 Pharmaceutical Product Development 
Development of successful pharmaceutical products drives profit. which in turn pennits fun her 
drug developmenl. Profit from sales occurs only after a marketable product has been produced and 
its associated developmental costs have been surpassed. In addition. sales for a successful product 
must also account fo r the cost of unsuccessful compounds that have failed at some stage during 
development. 
1.2.1 An Overview 
The drug discovery and development process im·olves elements from both regulatory bodies and 
industry (Figure I-I). The entire process spans prc-clinical laboratory research and development. 
through to clinical evaluation. and finally to post-marketing surveillance. It is in pre-clinical 
research. commonly referred to as Phase O. that new drug entities are screened and developed for 
eventual cl inical application to humans. Owing to rapid advances in areas such as comput ing 
technology. combinatorial chemistry. molecular and cell biology. and high-throughput screeni ng 
techniques. Slrong progress has been made in identifying potential lead compounds. Although such 
techniques have provided an increased number of potential new drug entities, this has not 
necessarily translated to fill increased number of drugs successfully reaching the marketplace [Grass 
& Sinko, 200 1]. 
Of all the NCEs screened in Phase O. only a small number ever progress beyond animal stud ies. 
From this small percentage it has been estimated that less than one quaner possess all the necessary 
phannacokinetic and phannacodynamic characteristics to successfully become marketable products. 
Increasing the number of NCEs progressing to the clinical trial phases then substantially increases 
the number offailures at this late stage. The bulk of drug development spending can be anribUled to 
these failures. and the IOtal amount has been estimated to be around 75% of all monies spent on 
drug development. Hence, the focus of drug development has expanded more and more to include 
procedures aimed at identifying potential fai lures as well as successes [Ekins el al.. 2000J. 
In the period 1968-1988. it was found that the major reasons for failure of NCEs in humans were 
unacceptable phannacokinetics (-40% of failures) and lack of efficacy (- 30% of failures) [Prentis 
et al.. 1988J. Unacceptable phannacokinetics can include poor absorption, distribution, metabolism, 
or excretion (ADME) characteristics. Poor phannacokinetics can also manifest as lack of clinical 
efficacy. Hence. the human pharmacokinetics of a compound plays a vital role in determining the 
suitabili ty of an NCE for further development. 
Screening for ADM E properties and toxicity is usually performed both ill vitro and with various 
animal models which are time-consuming and expensive [Norris et al.. 2000]. Even then. results 
may not always accurately renect the pharmacokinetics of a compound once it is administered to 
humans. Results gained from ADME screening are used to determine whether development of an 
NCE should continue to Phase I or not. 
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Figure I-I. General sequence of events involved in drug development (adapted from [Lesko et al .. 
20001). Black areas (II) represent time taken for regulatory processes, whilst clear areas represent 
scienlific process normally associated with industry. 
Early clinical testing in humans conducted in healthy subjects is aimed at detennining tolerated 
dose size, initial pharmacokinetic profiles, candidate delivery systems, and the relationship between 
plasma concentrations and phannacological effects [Peck et at. , 1992]. Preclinical screening may 
indicate an NCE with suitable phannacokinetic attributes. however. the majority of candidates do 
not succeed through the clinical testing phases. 
Owing to financial pressures and the need for more accurate predictive methods. research into 
methods other than ill vitro screening and animal models is a growing area. Computational 
techniques. often termed ill silica methods, have begun to playa larger role in the drug discovery 
process. Previously impossible computational tasks have become a matter of routine with the ever-
increasing power and availability of computers and software. III silica methods have gained 
popularity in vi rtual compound library screening [Walters et at., 1998]. three-dimensional (3D) 
phamlacophore elucidation [Terfloth & Gasteiger, 2001], and QSPR analyses [Ekins et at., 2000]. 
They are cheaper and quicker than performing ill vitro and animal experiments, although they are 
not yet as acceptable to regulatory authorities. Data taken from previously published work or from 
objective sources such as molecular structure have allowed prediction of important pharmacokinetic 
properties such as intestinal absorption [Wessel et al. , 1998], distribution parameters [Herman & 
Veng-Pedersen. 1994]. and binding characteristics [Wagener et aJ.. 1995; Loukas, 2001]. Both 
experi mental and ill silica techniques have advantages and disadvantages, and their roles in drug 
development will now be discussed briefly. 
1.2.2 III Vitro Screening and Animal Models 
The use of ill vitro and animal models allows research to be perfonned on a much cheaper and 
fas ter scale than in humans. Funhermore. safety issues and ethical requirements for humans are also 
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avoided. These methods aim 10 provide measurements regarding the potential NCEs which can then 
hopefully be correlated with human activity or pharmacokinetics. 
Most drugs are developed for oral administration so bioavailability of a compound is an important 
factor to consider. Oral bioavailability is dependent sequentially upon dissolution in the 
gastrointestinal (G l) tract. absorption across the physical barrier of the Gl membrane, and a first 
pass through the liver and lungs [Sietsema. 1989). Absorption occurs via either paracellular or 
transcellular pathways. Hence. absorption is influenced by permeability, molecular size. and 
hydrogen bonding characteristics (Smith & van de Waterbeemd, 1999]. Although not a measure of 
bioavailability. absorption is the first step in delivering an oral dose of a drug. 
One common technique for in vitro modeling of absorption is the Caco-2 monolayer system which 
is an immortalised human colon adenocarcinoma cell line. Caco-2 cel ls are enterocyte-derived cells 
possessing a microvillus surface and allow moderate to high-throughput screening of compounds. 
Another technique. Madin-Darby canine kidney (MOCK) cells in monolayer can be used in a 
similar functional manner to Caco-2 cells but do not require the 2-3 week culturing times Caco-2 
cells do (Pelkonen et al .. 2001]. 
Although both techniques allow reasonably fast screening of compounds. the major disadvantage is 
that they are considerably different from the situation ill 1';\'0. Compounding this are the inter-
experiment and inter-laboratory variations seen with these ill vi/ro techniques. Thus. cellular models 
can provide useful infonnation but are not complete in themselves. 
High-throughput screening is the rapid analysis of chemical libraries for biological actIvIty. 
Compounds are screened using automated miniaturised assays \\hich enable vast numbers of 
compounds to be tested in a short period of time {Inglese. 2002). 
Combinatorial libraries contain from hundreds to millions of compounds for testing. so examining 
the entire chemical space available to most companies would not be affordable. Efforts have instead 
been aimed at reducing the chemical space 10 those compounds for which manufacture and further 
development is a feasible proposi tion [Gobbi & Poppinger, 1998]. Searching such large numbers of 
compounds has increased the number of drug-like "hits" exhibiting potential biological activity. 
This has in turn placed more pressure on the subsequent step of assessing the potential NCEs for 
suitable pharmacokinctic properties. 
III I'il'o mctabol ism of test compounds is a serious problem in new drug developomenL Metabolism 
of compounds by various enzymes can also be screened using ill vitro high-throughput methods. 
Typically, hepatic microsomal or other liver or tissue homogenate preparations are incubated in 96-
well plates with individual compounds in each well. Reaction times and conditions are completely 
conlrolled. and extent of metabolism is compared with a standard. 
The aim to mimic ill \'ivo metabolism is not ah\ays fully achieved since drug metabolism is a 
mullifactorial process which usually involves multiple pathways (Gaviraghi et al.. 2001J. In 
addition. protein binding can limit hepatic extraction ill vivo and may not be accounted for using 
simply the in vi/ro scrcen. The major drawback with microsomal preparations. however. is the 
inconsistency between preparations which can lead to variable results [Spalding et al.. 2000). 
Allometric scaling is another method of screening potential NCEs for human application. It is based 
on the premise that human and animal anatomical. physiological and biochemical characteristics are 
comparable [Feng et al., 2000]. Once pharmacokinetic parameters have been determined in animals 
they can then be mathematically related to human pharmacokinetic parameters. Individually. there 
is no single animal which can be relied upon to accurately predict human phannacokinetics. 
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Consequently, data must often come from several different species to construct a one predictive 
model [Hussain et al.. 1993]. Correction terms can also be applied to allometric calculations to 
increase the accuracy of models. Allometric scaling has been applied to structurally diverse 
compounds [Feng el a!.. 2000) and for various phannacokinetic parameters [Jezeque1. 1994). 
Although allometric studies avoid experiments on humans. they are st ill subject to ethics approval 
and are expensive to run. As a result of the inherent differences between animals and humans. 
allometric models do not always lead to accurate predictions for a human clinical situation [Grass & 
Sinko. 2001]. 
1.2.3 III S ilico Screening 
Computational methods for ADME began with the classical QSAR models developed last century 
using lipophilicity (Hansch & Lien. 1968). Even though datasets were small and comprised of 
structurally similar compounds. the hypothesis that metabolism and activity could be modeled in a 
quantitative fashion based on structural considerations was pioneering. From these beginnings. 
much progress has been made using purely computat ional methods for compound screening. The 
scope of QSAR has evolved to account for the spatial arrangements of atoms in a candidate 
molecule. Interaction of a molecule with a receptor or enzyme is dependant upon the 3D 
configuration and conformation of that molecule: good steric arrangement of atoms and functiona l 
groups al lows a more positive interaction. Once a 3D pharmacophore has been generated for a 
known agonist or substrate. screening of potential cand idates for that particular receptor or enzyme 
may then commence. Other computational techniques have been combined with 3D QSAR. for 
example comparative molecular field analysis (CoM FA) which estimates steric and electrostatic 
interactions bet\\·een a molecule and target binding site, and the VolSurf/GRID procedure which 
calculates energy· favourable sites around a molecule and converts them into selected molecular 
descriptors [Ekins et at.. 2000]. 
One of the critical requi rements for these ill silicD sc reening techniques is the availabil ity of virtual 
libraries of compounds containing structures able to be screened. If the number of compounds 
available for ill vitro high·througput screening is vast. then the number of theoretical structures 
possible in virtual libraries is almost incomprehensible. A maximally diverse virtual library is 
neither practical nor possible. so attempts must be made to limit the size of the library. Compounds 
should be selected first on the basis of being syr.thesisable products: lengthy. expensive and low 
yield reactions \"ould most likely not produce an economically viable product. Another method may 
be to restrict compounds to structures approachirg those of current marketed drug products. The 
majority of commercial drugs can be represented by a limited number of structural or functional 
scaffolds [Bemis & Murcko, 1996). 
A scaffold is the basic structural element used as the starting point for the generation of chemical 
libraries through chemical modification. There are two basic scaffold types. the functiona l scaffo ld 
and the structural sca ffold. The functional scaffold is a molecule with specfic biological activity 
directed toward a molecular target. For example. only chemical structures known to be susceptible 
to a particular enzyme may be included. A functional sca ffold is a lead compound used for the 
generation of focused libraries to optimise specific lead properties (eg potency, selectivity, or 
bioavailability) while maintaining the basic activity. 
Because active molecules are the uitimale goal of every lead or drug discovery project. libraries 
based on functional sca ffolds with proven activity are the most useful. The structural scaffold is a 
molecule with certain structural features (eg specific ring systems, chiral cent res, or functional 
groups). Structural scaffo ld libraries may be more complementary to an existing generic library for 
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hit and lead search over a wide range of target classes. These libraries can increase available 
chemical space and fill structural gaps and may therefore be more universally applicable than 
functional scaffold-based libraries. 
Three types of libraries need also be defined: general, focussed. and targeted. In order of specifici ty. 
general libraries are the least specific and are designed to be arbitrarily of broad interest in high-
througput screening. Focussed libraries are aimed at a family of related targets. for example 
cytochrome P450 (CYP) 2C9 substrates. whereas targeted libraries are spec ific for one particular 
binding or activity endpoint (Walters et al., 1998]. 
Such libraries may also be screened for desirable structural characteristics. It is known that 
hydrogen bonding. lipophilicity. and molecular surface properties can affect drug transport and 
membrane permeation [Stenberget al.. 2000). These factors play an important role in bioavailability 
and. hence. suitability of a drug for manufacture as an oral formulation. Simple methods can be 
employed such as counting the number of hydrogen donors and acceptors. although more complex 
methods may be required for calculation of lipophilicity and molecu[ar surface properties. The 
"Rule of Five" has been employed as a general guideline in industry to limit the size of vinual 
libraries to compounds likely to be adequately absorbed from the intestine [Lipinski et al.. [997]. 
The rule was developed upon examination of 2245 drugs from the World Drug Index (WDl) that 
were believed to have entered Phase II trials and were orally absorbed. According to the rule. 
compounds are deemed to have poor intestinal absorption if any two of the following conditions are 
met: 
=> There are more than five hydrogen-bond donors. 
=> The calculated log P (clog P) is greater than five. 
=> The molecu[ar weight (MW) is over 500. 
=> There are more than 10 hydrogen-bond acceptors. 
Oxygen and nitrogen atoms are defined as being hydrogen bond acceptors. and -NH or --OH groups 
are defined as being hydrogen bond donors. Calculated log P values may be determined using either 
a fragmental or molecular additivity approach depending on the nature of the dataset [Lipinski et 
al.. 1997]. The Rule of Five does not definitively categorise all well and poorly absorbed 
compounds. although it is simple. fast. and provides a reasonable degree of classification. 
1.3 Modeling Techniques in Pharmacokinetics 
Modeling provides a means to describe and understand data. It can also be useful for predictive 
purposes. Using a mathematical model such as a set of equations. large volumes of data may be 
summarised to provide a simpler representation. Depending on the modeling technique. 
pharmacokinetic data may be analysed using the model constructed. Pharmacokinetic models are 
relatively si mple mathematical tools that represent com plex physiologic processes. Thus, insight 
into mechani sms involved in pharmacokinetics, such as distribution and elimination. may be 
gained. Models which have been adequately validated can then be used fo r predictive purposes 
[Bourne. 1995]. This may be useful, amongst other things, in aiding lead compound se lection or for 
failing un suitab le compounds early during the developmental processes. 
Different modeling approaches can be mOTe or less useful for a given modeling task. [t is essential. 
therefore. to select the most appropriate modeling technique for each situation. ANNs were 
explored in the present wok because of their demonstrated ability 10 develop predictive data-driven 
models. Other methods may be more useful if the aim is to. for example. focus on mechanistic 
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relationships in pharmacokinetics. Nevertheless, the flexib le nature of soft computing makes ANNs 
a potentially useful tool in predictive pharmacokinetic modeling. Such flexibility dictates that 
replicate experiments be performed to provide a measure of experimental precision. 
A crucial aspect of modeling for predictive purposes is validation of the final model. Validation 
involves testi ng the ability of suc h a model to make predictions. An unvalidated model is only 
useful for the data it was constructed on. Tlltls. model testing using a cross-validation technique 
(Section 2.6.2) or independent testing compounds is often employed. Validation of a model 
provides a measure of ils predictive abi lity and/or potential utility. 
1.3.1 Non Structure-Based Methods 
The focus of this monograph is on structure-based methods of modeling. however non structure-
based methods will be mentioned briefly here for completeness. Three approaches that have been 
suggested for pharmacokinetic modeling include the com partmental approach, physiologically 
based methods. and model-independent techniques. 
The compartmental approach is an empirical approach which is based on a simple compartmental 
model. These compartments have no strict physiological or anatomical basis. The body is 
represented by a number of theoretical compartments that communicate reversibly with each other. 
The compartment can represent a body volume or,just as easily. it could represent a chemical state 
such as the metabolite of a drug. This approach usually uses either one or two compartments. 
Compartments are loosely considered a tissue or group of tissues with similar blood flow and drug 
affi nity [CUller. 1978]. Since there is more mathematical than physiological relevance for the 
parameters obtained in compartmental pharmacokinetic models, they cannot be used to extrapolate 
between species or provide mechanistic information about drug pharmacokinetics. 
Despite its simplistic nature, many useful quantities can be derived using this approach and by 
comparing pred icted values with aClUal data. They are also useful when only plasma or blood 
concentration-time data are available without necessarily requiring tissue concentration data. 
A physiologically based pharmacokinetic (PBPK) model ident ifies the compartments with actual 
body spaces. Such models are a great deal more complex than simple compartmental models. PBPK 
modeling incorporates physicochemical data as well as anatomical and physiological data from 
animals or humans to develop models for pharmacokinetic prediction [Grass & Sinko. 2002]. These 
models describe the mechanistic inter-relationships between ADME processes. Hence. they are 
more adaptable to clinical therapy and for changing situations. PB PK models can also be used for 
predict ive purposes. PBPK models may provide useful information describing drug disposition and 
metabolism [Poulin & Theil. 2002] but require a large number of experimental parameters for 
mode l construction [Balant & Gex-Fabry, 2000]. They are. therefore. rare ly used in early drug 
discovery or development. 
Both compartmental and PBPK models require multiple data points from a single subject. In 
contrast, population pharmacokinetic model ing can use pooled data from multiple subjects. This is 
particularly useful when pharmacokinetic data is "sparse," that is, when only limited data is 
available. In addition to sparse data. rich data can also be used for population pharmacokinetic 
modeling either separately. or in combination with sparse data [Tell et a!.. 1998]. One of the main 
advantages of population pharmacokinetic modeling is that data is gathered from a number of 
sources so fewer samples per subject are requi red. Another advantage is thaI pooled data allows 
conclusions regarding inter-subject variability in pharmacokinetics to be drawn. Disadvantages are 
that separate models must be developed for each drug and models are only representative of the 
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species in question. Therefore. population phannacokinetic modeling is nOI often used in Ihe early 
Slages of drug development. 
The model-independent approach is purely mathematical [Kuhle et al.. 2005]. It avoids recourse 10 
kinetic parameters thaI may not be valid. and models developed tend to be less complex. This 
approach is good for modeling ADME values but gives no physiologically relevant information 
about drug propenies. 
1.3.2 Structure-Based Methods 
The fundamental assumption in pharmacokinetic modeling based on structural considerations is that 
changes in molecular composition and atomic arrangement are quantitatively responsible for 
changes in drug pharmacokinetics. Such an assumption is based on the success of early QSAR 
models which demonstrated the relationship between pharmacologic activity and molecular 
structure [Seydel & Schaper. 1981]. Most of the reponed activity values were from iii vilro 
experiments using isolated organs or enzyme preparations. The challenge in moving from cellular 
systems to whole-body systems was. and still is. considerable. It has been proposed that structural 
variations may have a more obvious effect on phannacokinetic parameters than phannacological 
activity since they may be controlled to some extent by the physicochemical propenies of a 
molecule. For example. the crossing of a biological membrane may be related to the lipophilicity of 
a molecule and. since the structure of biological membranes is consistent throughout the body. a 
consistent relationship between lipophilicity and membrane penneability should be expected 
[Seydel & Schaper. 1981]. The complexity of living organisms dictates that no such simple 
correlation is apparent: although relationships can be approximated they may not entirely be 
explained by structure. 
1.3.2.1 Mllitilinear Regression 
The first QSAR models related physicochemical characteristics of a molecule with activity using 
mathematical regression equations. The Hansch analysis. or linear free-energy related (LFER) 
approach works on the principle that physicochemical propenies of a compound are additive and 
may be combined linearly to approximate activity. This can be summarised in the following manner 
(Equation I-I): 
y = PIXI + P1X1 + ... + PiX. +6 Equation I-I 
where y is the independent variable and may be a biological activity or propeny. k is the number of 
independent variables, P, ... Pt are Ihe regression coefficients. and 6 is a constant. The coefficients 
are detennined by means of multiple linear regression using the least squares method. The 
assumption in LFER modeling is that the different magnitudes of a biological activity or property 
within a compound series correspond to changes in the free energy of the compounds which occur 
when reactions or interactions take place. The gradations of both activity/propeny and free energy 
are supposed to be linearly related [Hansch & Fujita. I 964J. Free energy is difficult to detennine in 
biological systems so constants representative of free energy can be used. These constants include 
rate constants. and steric. electronic, and lipophilic parameters. 
One of the advantages of modeling using such si mple equations (Equation I-I) is that direct 
relationships between variables and the target activity/propeny values are evident. A positive 
coefficient corresponds to an increase in the target value whilst the opposite is true for negative 
coefficients. The absolute size of the coefficient indicates the magnitude or imponance of Ihe 
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contribution of a particu lar variable. Thus, if all data are scaled appropriately. a large absolute 
coefficient indicates an important contribution by a particular descriptor whereas the smaller the 
absolute value ofa coefficient the less of an influence that descriptor has on the target value. 
A disadvantage with mul tilinear regression (MLR) is that in general about fou r or five compounds 
(patterns) at least are requi red for each variable used. This is a problem with small datasets since the 
number of descriptor variables available are thus restricted. Such datasets may not provide 
sufficient information to enable construction of a mean ingful model. Furthermore. the relationship 
between the number of panerns and number of variables needs to be monitored in multilinear 
regression to avoid chance effects [TopJiss & Edwards. 1979J. Another disadvantage is that drug 
data often contains correlated or skewed information thai can lead to the construction of poor 
regression models [Butina et aI., 2002]. 
Ta ble 1·1. Human QSPkRs using multilinear regression. 
Pharm acokinet ic Drug Data Equation Variables Re ference 
Para metel' 
Half life sulfonamides log P [Seydeletal.,1973] 
Epidermal absorpt ion aliphatic alcohols log P [Lien, 1975] 
Protein binding penicillins log P [Craig & Welling. [977] 
Volume of distribution penicillins P [Watanabe & Kozaki. 
1978a; Watanabe & 
Kozaki. 1978b] 
Metabolism by aliphatic amines log P, pKa (Kubunyi, 1979] 
monoamineoxidase and alcohols 
Clearances, ~·adrenoceptor pKa, K'.'·F [Hinderl ing et al.. 1984b; 
mean residence time, antagonists ( octanol/buffer Hinderling et a!.. 1984a] 
volumes of distribution partition coefficient) 
Clearances, non-congeneric MW. intrinsic and [Herman & Veng-
mean residence times, compounds (17) alcohol solubilities, Pedersen. 1994] 
volumes of distribution protein bindi ng. 
distribution coefficient 
Volume of distribution Non-congeneric Fraction ionised . [Ghafourian et aI., 2006]' 
compounds (129) electrotopological 
indices, electrostatic 
potential, log P. lipole 
"MLR combined \\·ith GA 
Early QS PkRs relied mostly on experimental variables to develop multilinear regression equations 
for a range of pharmacokinetic parameters. The most common variable used, log P. has been 
correlated with many different ADME parameters in both animals [Winningham & Stamey. 1970: 
Mart in & Hansch. 1971 ; Seydel et aI., 1980; Blakey et al., 1997] and humans (Table I-I ). Early 
QSPkRs were generally constructed using only small congeneric datasets. Experimental values 
were obtained for each study individually to ensure consistency of results. Animal data was much 
easier to obtain than human data so animal QS PkRs are more prevalent in the literature. Success of 
early QSPkR studies for prediction and drug development was limited due to the small number of 
drugs and types of descriptors used. [n addition. models were developed to relate descriptor 
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variables with pharmacokinetic parameters of drugs only present in the training sel. 
Early models were generally not further validated which limited their usefulness. 
One recent study. however. combined MLR and GA techniques for prediction of volume of 
dist ri bution for a structurally diverse series of drugs [Ghafourian et a1.. 2006]. The final regression 
equations incorporated both theoretical and experimentally-derived descriptors and were tested 
using a leave-25%-olll technique. Consensus model accuracy was determined to be 72.2% of 
predictions to have less than a two-fold error. 
While obviously useful, log P does not provide all the information about a moletule necessary for 
construction of unlimited sorts of structure-property relationships. Additional physicochemical 
descriptors have been incorporated in models over time and eventually theoretical descriptors were 
included as well [Genty et aI., 2001]. Even so. the limitations of multilinear regression were sti ll 
apparent: numbers of descriptors needed to be contro lled and validation of models remained a 
challenge. 
/.3.2.2 Artificial Neural Networks 
In comparison with multilinear regression. ANNs are more flexible, robust. and better at prediction 
[But ina et al.. 2002]. ANNs are inherently nonlinear and adaptive systems that have demonstrated 
robustness with the often complex and noisy experimental data in the pharmaceutical field [Turner 
et al., 2003a]. Their introduction into the area of pharmacokinetics has been relatively late 
compared with other scientific and industrial fields. ANNs have found use in clinical monitoring to 
match pharmacokinetic profiles with pharmacodynamic effects [Minor & Namini, 19961, and for 
predicting patient creatinine clearance based on physiological variables [Herman et al.. 1999]. In 
both these studies, ANNs produced results superior to regression or other modeling methods alone. 
and conclusions were that ANNs would be of particular benefit in those clinical si tuations. 
Similarly. another study used physiological and demographic data to predict the pharmacokinetics 
and pharmacodynamics of repaglinide. an oral hypoglycaemic agent [Haidar et al.. 2002]. In 
addition to obtaining acceptable predictions. the ANN technique also allowed identification of 
significant covari ates. It is important to note that ANNs do not present mechanistic information so 
other methods must be used should the mechanisms underlying pharmacokinetics be required. Even 
so, simi lar predictive models have been obtained using ANNs when compared with mechanistic 
modeling techniques [Nestorov et al.. 1999]. 
ANNs have also been compared with conventional programs for construction of predictive 
population phannacokinetic models. In comparison with the population pharmacokinetic modeling 
program NONMEM [GloboMax LLC, 1998], ANNs demonstrated lower absolute and prediction 
errors [Chow et al. , 1997]. Modeling of the pharmacokinetic data was accomplished \"ell by both 
methods. however. results presented were not validated against external data. A more recent study 
trained both ANNs and NONMEM on two thirds of a 622 point dataset and found that prediclion of 
the remaining one third of the data was consistently superior using the ANN model [Tolle et al.. 
2000], In both these studies, the same covariales were used for ANN and NONMEM model 
construction. Hence. there appears to be good potential for ANN application in population 
phannacokinetic modeling. 
QSAR studies have benefited from the lise of ANNs for over a decade [A oyama et al.. 1990], 
Following the progress of QSAR. development of QSPkRs using ANNs has also advanced. Both 
physicochemical and theoretical descriptors have been used successfu lly in ANN QSPkR studies. 
either individually or in combination [Ritschel et al.. 1995; Agatonovic-Kuslrin et al.. 2008]. The 
trend has been towards completely in silico models as described earlier. since Ihe speed associated 
with ANN models coupled wilh cheaper and more po\"erful computational methods has made this 
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direction more feasible. A more detailed discussion of the application of ANNs in QSPkR modeling 
is given in Section 1.6. 
1.4 Artificial Intelligence Systems 
Soft computing methods have been used to varying extents in pharmaceutical research. ANNs have 
been the most popular due their intrinsic nonlinearity and characteristic robustness. They have been 
termed "universal approximators" since by varying network architecture it is poss ible to model 
almost any given situation [Haykin. 1994}. In addition 10 simply modeling a system. their use in 
prediction has also received growing attention. Multilayer perceptron (MLP) and radial-basis 
function (RBF) ANNs have been used more extensively than other ANN paradigms. and they will 
be discussed in the proceeding sections. The Kohonen topology-preserving map. otherwise known 
as self·organising map (SOM) is a form of ANN which may be used as a clustering tool. In theory, 
relationships in a multidimensional space are mapped onto the surface of a torus so that the 
Euclidean di stance separating each point is equal. Sectioning one part of the torus and unbending it 
produces a cylinder. Sectioning the cylinder along its length allows it \0 be unrolled to form a 
rectangle. Hence. the original points now reside on a 2·dimensional (2D) plane. One advantage of 
self-organising maps is that target values arc not required for initial model construction. Genetic 
algori thms (GAs) are evolutionary systems based on chromosomal recombination and selection. 
They can be used as stand·alone models however they are often used in combination with other soft 
computing methods such as feed · forward back·propagation ANNs to select optimal subsets of 
descriptors in QSARlQSPR studies [Ternoth & Gasteiger. 2001]. 
1.4.1 Multilayer Perccptron ANNs 
ANNs are mathematical models inspi red by the structure of the biological brain. They are 
composed of many individual processing units or artificial neurons which arc extensively inter-
connected to form a network. Emulation of brain function was based on the hypothes is that the 
information in a brain resides in the strength of connections between neurons and not in the internal 
state of the neurons themselves [Bucinski et al.. 2000J. Learning is simp ly the adjustment of the 
strengths associated with each connection. For this reason. connections bet,\een neurons are known 
as ·'weights:· The neurons arc connected to one another in parallel \\·hich provides their 
characteristic speed. robustness. and generalisation ability (Maddalena. 1998). 
Mult ilayer perceptrons arc of the feed-forward back·propagation class. They are composed of 
neurons organ ised into an input layer, one or more hidden layers. and an output layer (Figure 1-2). 
The number of input neurons is equal to the number of variables, and the number of output neurons 
is equal to the number of largets being predicted which in most cases is equal to one. The number of 
neurons in the hidden layer can be either one. for studies which parallel multilinear regression, or 
greater than one for studies deal ing with nonlinear data [Aoyama & Ichikawa. 1991}. In each layer 
there is usually also an extra bias neuron which is not connected 10 the neurons in the previous 
layer. The bias neuron provides a magnitude adjuslment 10 the input values so that they are in the 
correct range for processing by other neurons [Swingler. 1996]. Since the bias neuron is connected 
to each and every neuron in the hidden and output layers. the relationship bet\\een input variables 
and target output is not easily traceable. As mentioned previously_ in multilinear regression the 
influence of each variable is proportional to the size of its coefficient whereas this is not necessarily 
the case with multilayer perceptrons. In order for the multilayer perceptron to make predictions it 
must first be trained as described in the General Methodology (Section 2.6.1.1). 
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Multilayer perceptron ANNs have been widely utilised in the pharmaceutical sciences. In a clinical 
setting. ANNs were used to monitor the pharmacodynamics of short·acti ng neuromuscular blockers 
[Lend I et al.. 1999]. ANNs were chosen since they offered a fast and controllable mechanism for 
prediction without the need for more costly biopharmaceutical data. Compared with conventional 
closed-loop controllers. results using the ANN were encouraging, suggesting a potential use for this 
technique in this and other clinical settings. In another clinical study both pharmacokinetic and 
phannacodynamic relationships were analysed using ANNs [Minor & Namini. 1996]. It was also 
suggested that ANNs may be useful for time-dependent modeling and aiding in the development 
and analysis of clinical trials. 
Input 
layer 
Weights 
Hidd.n /~ layer(S)~
N"ro", ~' 
Output ~ 
layer • • • 
Figure 1-2. Schematic representation ofa multilayer percept ron ANN. 
Immunosuppressant therapy in organ transplant recipients requires close monitoring of drug 
concentrations to ensure adequate immunosuppression. Conventional methods rely on 
measurements of trough blood concentrations. although free plasma concentrations and tWO hour 
post-dose concentrations are also being examined. Using population data. clinical monitoring of 
peak and trough serum concentrations of gentamicin was exami ned [Brier & Aronoff. [996]. 
Prediction of peak concentrations using ANNs was comparable with models constructed using 
NONMEM, while prediction of trough concentrations was superior using ANNs. 
In other predictive applications the scaling-up of allometric data to predict human pharmacokinetic 
parameters has been performed with ANNs. [n one study, animal data taken from the literature was 
used to predict human volume of distribution and clearance values [Hussain et al. , \993]. Although 
ANNs were shown to provide acceptable models, problems included the requirement of a 
substantial amount of training data which may not always be readily accessible. However. it was 
also shown that existing animal data was able to be supplemented with theoretical data from drug 
structure. Furthermore. drug physicochemical data may also be included for construction of 
pharmacokinetic models [Ritschel et aI., 1995]. Prediction of clearance and volume of distribution 
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using ANNs with such information was shown to be similar to ill I'ilro estimations, so no 
superiority of either technique was apparent in that respecl. However. time and cost savings gained 
using the ANN indicated that it was potentially a more useful technique. As with the majority of 
earlier studies using theoretical descriptors. linle allempt was made to explain the relationship of 
such descriptors Wilh the phannacokinetic parameters in question. 
1.4.2 Radial-Basis function ANNs 
Radial-basis func tion ANNs differ from multilayer perceptrons in that the nonlinear transformation 
of data occurs on ly in the hidden layer and not elsewhere [Yao et al.. 2002bj. Radial-basis function 
ANNs belong to the class ofkemel estimation methods and employ a transfer function represent ing 
a bell-shaped Gaussian response surface. In contrast. the transfer func tion in multilayer perceptrons 
is generally sigmoidal (Figure 1-3). Although they only have three layers of neurons available. 
radial-basis function ANNs are functionally comparable to multilayer perceptrons. Details of 
training are given in General Methodology (Section 2.6. 1.2). 
a 1.0 b 1.0 
0.5 0.5 
0.0 I .L >........ 0 .0 I ......--
o 
" 
100 o 
" 
20 
" 
Figure 1-3. Transfer function for a) hidden neurons in 8 radial-basis funct ion ANN. and b) neurons 
in a multilayer perceptron. 
Radial-basis function ANNs have not been used as extensively as multi layer perceptrons in 
phannacokinetics or elsewhere. For the same modeling task they generally require more neurons in 
the hidden layer than the latter which leads to increased network complexity. Jt has been suggested 
that complexity of a network can influence the training and predictive performance of a model. The 
analogy applied is that multili near regression studies require a certain minimum number of patterns 
per optimisable panuneter. That is true for any modeli ng technique. however. the analogy is not 
ent irely applicable to ANNs in general since they arc nonlinear systcms. 1·lence. the relat ionship 
between the complexity of the model and the number of patterns depends specifically on the nat ure 
of the model itself [Turner et al .. 2oo3a]. 
One advantage of radial-basis function ANNs Q\'er multilayer percept ron ANNs is the speed at 
which they are trained. [n one QSPR study using 233 compounds both paradigms were directly 
compared [Tettch et al .• 1996]. [t was found that resul ts using both paradigms were comparable for 
both training and validation. However. radial-basis function ANNs trained fasler and were less 
likely to fall into local minima than multilayer perceptrons that employed sigmoidal transfer 
functions. Further comparisons were also made with li near modeling techniques which were found 
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not to be as useful as ANN models. A similar conclusion was drawn in other comparative studies. 
for exam ple, in a recent QSPR for benzene derh'atives employing quantum mechanical values as 
input descriptors [Wang et al.. 2002]. 
Since radial-basis function ANNs train relatively fast. they are well suited to problems involving 
large dalasets with numerous descriptor variables. Several studies have generated a number of 
theoretical descriptors and then selected only a subset to use in the final model. One such study 
generated 35 topological descriptors and selected a subset of 9 for the final QSPR of 173 
compounds [Yao et a1.. 2002a]. Another QSPkR for intestinal permeability constructed at a 
predictive model of 15 descriptor variables from a total of 57 generated for 86 drugs {Agatonovic-
KUSlrin el al .. 2001]. Both studies employed different methods for selection of optimum descriptors, 
but all models were suitably cross-validated to ensure soundness of results. The fact that radial-
basis function ANNs require a greater number of hidden neurons than multilayer perceptrons does 
not usually affect training time significantly. 
1.4.3 Generalised Regression Neural Networks 
More recently there has been increasing interest in the use of generalised regression neural networks 
(GRNN) in phannocokinetic modeling [Yap et al.. 2006]. These also have the advantage of fast 
training but the disadvantage of often ambiguous descriptor interpretation. One direct comparison 
of GRNN. multilayer perceptron. and mul tilinear regression modeling of blood-brain barrier 
penetration of 159 compounds [Yap & Chen. 2005} utilised principle component analysis to select 
training and val idation compounds. a genetic algoritm (GA) approach for descriptor selection. and 
further principle component analysis for descriptor analysis (see Section 1.4.5). Thi s technique was 
extended to human seum albumin binding and milk/plasma partitioning models derived from 93 and 
122 structurally diverse compounds respectively. Only theorectically-derived descriptors were 
included which. once explained by principle components. made interpretation of individual 
descriptors challenging. For all three datasets the GRNN approach yielded superior results although 
predictions and comparisons were not greatly convincing. 
Another study [Niwa. 2003] used a known set of 86 compounds and their human intestinal 
absorption (H 1A) values [Wessel et a1.. 1998] to lest GRNN and probabalistic neural network 
modeling capabilities. Predictions were comparable to, although not as accurate as. the original HIA 
study. The methods employed proved useful in the speed, simplicity of model and desc riptor 
generation. and interpretation of the final model. It remains, however. that improvements are 
necessary in terms of drug dataset size and quality. 
1.4.4 Other Soft Computing Methods 
Genetic algorithms are an evolutionary technique \",ell suited for selection purposes. As such. they 
have been used to reduce the number of available compounds [Gobbi & Poppinger. 1998] and for 
compound selection optim isation to identify bioactive molecules [Gillet et a1.. 1998J in virtual 
libraries. As well as being a usefu l tool in isolation. genetic algorithms have often been applied in 
combination with other modeling techniques such as ANNs. These genetic neural networks (GNNs) 
provide an automated pruning technique fo r studies involving large numbers of descriptor variables 
[Zupan & Novic. 1999]. Comparatively. GNNs have matched QSAR results obtai ned usi ng manual 
pruning, and have the added advantages of speed and unbiased descriptor selection [So & Karplus, 
1996]. With the increasing number of theoretical descriptors able to be generaled from drug 
structure, GNNs have also successfully aided the selection of key descriptors for QSPR models 
constructed using multilinear regression [Tumer et al.. 1998], and ANN [Agatonovic-Kustrin et a1 .. 
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2001] methods. Although genetic algorithms present a useful altemative to manual selection of 
descriptors, they tend not to be used for exhaustive searching or correlating since they are 
com putationally expensive relative to other in silico approaches. Nevertheless, GAs have recently 
been utilised in QSPkR studies as stand·alone models using simple theoretical descriptors [Wang 
2006. Cheng 2007] with encouraging resul ts. 
A Kohonen self-organising map represents an unsupervised neural network paradigm, and is 
essentially a 20 representation of a mult i-dimensional space [Kohonen. 1997]. With respect to 
pharmaceutical applications, a drug may be described by numerous physicochemical or theoretical 
descriptors and then represented by a position on a 20 map relative to other com pounds. Thus, 
similar compounds are clustered together on the self-organising map whilst different compounds are 
positioned away from each other. This technique, known as k-nearest-neighbour (kNN). has been 
used to classify pharmacologically active molecules amongst non-congeneric datasets [Bauknecht et 
al.. 1996] and also to locate potentially useful anticancer drugs [van Osdol et al .. 2000]. Clustering 
of compounds according to odour properties has also been performed [Audouze et al .. 2000] but it 
was found that appropriate description of the compounds for projection onto a self-organising map 
was problematical. Useful self-organising maps have been created in other areas such as protein 
surface [Stahl et at.. 2000] and molecu lar surface potential mapping [Gasteiger et aI., 1994]. One 
combined k-NN/simulated annealing study achieved predictive results for Vss and CL comparable 
to other soft computing methods, and superior to PLS modeling [Ng 2004]. 
Fuzzy logic is characterised by a mathematical framework that lacks well-defined boundaries. The 
lack of strict boundary conditions allows nexibili ty in classification problems, and fuzzy sets have 
successfully been developed to classify compounds according to their chemical composition [Pop et 
aI., 1996]. and similarity [Maggiora & Mezey. [999]. [n pharmaceutics, fuzzy sets have been 
applied in clinical drug dosage monitoring [Kem et at.. 1997; Shieh et a!.. 2002], and prediction of 
serum pharmacokinetics [Sproule et aI. , 1997]. When compared with conventional population 
phannacokinetic modeling using the same data. fuzzy logic provided comparable results and 
allowed detennination of important covariates. Other pharmacokinetic stud ies have used fuzzy 
methods to predict human bioavailability and volume of distribution [Hirono et a!.. 1994a; Hirono 
ct al.. 1994bJ. These studies grouped compounds according to known bioavailability values and 
furthe r subdivided groups accordi ng to broad chemical composition. Even though fuzzy logic 
appears to be a useful alternative to conventional modeling. further development is requi red to 
enable prediction of unknown compounds. 
1.4.5 Descriptor Selection 
Optimum descriptor selection remains a fundamental problem in QSARlQSPR studies. Many 
descriptors may be considered for inclusion in a model. however not all may provide useful 
information and indeed some may even be detrimental. The aim of descriptor selection is to 
improve model generalisation by reducing unnecessary data (Tetko et al.. 1998). 
Ear[y multilinear regression models utilised smaller numbers of physicochemical descriptor 
variables sllch as log P and association constants. As the field of QSARlQSPR grew, additional 
ways of describing compounds were realised and methods had to be established to select relevant 
descriptors. Since multilinear regression provides a direct relationship between a descriptor and the 
output space, norm alised descriptors with very low coefficients are considered not to contribute 
significantly to a given model and so may be removed without much harm. More complicated 
stepwise regression techniques have also been implemented. These involve identification of an 
initial model and then repeated alteration of the model from the previous step by the addition 
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(forward stepwise) or removal (backward stepwi se) of a descriptor variable. The search is 
terminated when stepping does not further improve the model. 
Partial least squares regress ion is an extension of multilinear regress ion. but derives factors from the 
descriptor variables to maximise the covariance between the descriptor and output spaces [Bjork & 
Danielsson.2002). 
Clustering methods group similar descriptors together to minimise the variance within clusters but 
maximise variance between clusters. From these clusters, suitable descriptors may then be selected 
which should represent a substantial portion of the information contained in the entire descriptor 
set. 
Principal component analysis (PCA) derives descriptors representative of the whole descriptor 
space but does so by linearly combini ng variables to maximise variance between the individual 
principal components [Bruni et a1.. 2002J. All these descriptor selection methods have been used to 
some extent in pharmaceutics [Abuzaruraloul et a1.. 1998] and QSAR , although other genetic 
algorithm and ANN techniques have proven more effective [Winkler et aJ.. 1998]. 
As described earlier. genetic algorithms provide an effective means of descriptor selection which 
may then be combined with, for example. ANN modeling [So & Karplus. 1996]. Chromosomes. 
representing the entire descriptor space. are composed of genes. which represem individual 
descriptors. and randomly crossed-over to simulate biological evolution. A fitness function applied 
to the resultant offspring retains the better·performing chromosomes, and then the process is 
reiterated until the chroillosome with the best genetic composition has evolved lZupan & Novic. 
1999]. Analogous to biological systems. mutations are sometimes incorporated to help offspring 
avoid local minima. One limitation with genetic algorithm searching is that chroillosomes are often 
constrained 10 a fixed length. which may restrict the characteristics of the terminal offspring. 
Variable· length chromosomes have been used. however. this attenuates the problem of lengthy 
training limes [Vasri & Hartsough. 2001]. 
In contrast. studies using ANNs alone are computationally inexpensive. Such studies often include 
the entire descriptor set initially followed by descriptor selection being perfonned on a continuous 
basis until an optimum subset is achieved. Various selection or pruning techniques exist which aim 
to eliminate redundant weights and/or descriptors. thus leaving only those offering a significant 
contribution to the model. 
Pruning may be divided into sensitivity and penalty term methods. and can be implemented either 
manually or incorporated wilhin the training algorithms. Sensitivity-based methods have been 
examined and it has been found that simpler magnitude-based algorithms performed as well as more 
sophisticated error-based algori thms [Tetko et aJ.. 1996]. Penalty tenns were also shown to be 
useful in removing redundant weights and were thus able to accentuate the importance of certain 
descriptors with respeci to the target output space. Manual selective pruning has been used 
successfully to reduce the number of descriptors and, although time-consuming. has the advantage 
of allowing grealer control over the pruning process than automatic algorithm-based techniques 
[Maddalena & Johnston. 1995]. 
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1.5 Descriptors Used in Modeling 
Classical physicochemical descriplOrs such as log P are not available for all known chemical 
entities. Conversely. theoretical descriptors may be calculated for all chemical entities should the 
structure be known [Oevil1ers, 1999]. Descriptors may be a scalar representation such as alom-
counls. or rely on a matrix. for example topological indices. or require lattice-type information to 
allow calculation of 3D desc riptors. There are currently over a thousand theoretical descriptors that 
have been applied to chemical - and drug-related problems. Many theoretical descriptors contain 
simi lar infonnation and this is particularly true for descriptors derived for smaller molecu les or for 
structurally related compounds. [t is generally accepted that appropriate methods should be 
undertaken to limit the number oftopo[ogical indices in a study to those containing independent and 
useful infOTTTIaiion (Basak et at.. 2000a). Hence, suitable clustering or pruning is required to ensure 
that redundant descriptors are not included in the modeling process. 
Independent descriptors are those which are not sign ificantly linearly correlated with one another, 
thus, their information content is independent of 1hat of other descriptors. To maintain diversity of 
information highly correlated descriptors are oOen excluded from a model. Even so, correlated 
descriptors may still be included in a successful models since, unless identical, they all contain a 
certain amount of independent and possibly useful informat ion [Consonni et at.. 2002]. 
Some of the more important theoretical descriptors and those relevant to the studies presented here 
will be described in the proceeding sections. 
1.5.1 Constitutional Descriptors 
Constitutional descriptors are the simplest of all theoretical descriptors, although they are not 
strictly classed as topological indices. They encode basic information such as the number and type 
of atoms in a molecu le, and they also include counts offunctiona[ groups. 
There are two ways of presenting constitutional descriptors: the first is using a binary system where 
the presence or absence of a particular moiety is denoted by a one or zero respectively. The second 
and more common method quantifies the number of cases of each moiety. For example. bepridil is 
represented in a different manner according to each system (Table 1-2). The assumption behind 
constitutional descriptors is that variations in atomic and functional group composition influence 
whole molecule properties. Indeed, this assumption underpins QSAR studies for drugs defined by a 
common template structure and allered at various substituent positions around that template 
[Maddalena & Johnston, 1995]. 
The fact that constitut ional descriptors are easily interpreted is a distinct advantage over more 
complex topol ogical indices. Constitutional descriptors have been used for prediction of 
physicochemical parameters [Burden. 1996] through to entire QSPkR analyses in combination with 
other descriptors [Agatonovic-Kustrin et al.. 2001], wang 2006]. For prediction of biological 
activity. Ihe ability of constitutional descriptors to encode useful information appears 10 be better 
suited 10 congeneric series of compounds since deviations in activity can be directly attributed to 
variations in substituents [Jaen-Dltra et at.. 2000]. 
Application 10 non-congeneric series of compounds has been performed. although, to account for 
the larger differences in molecular structure, usually more complex descriptors are required as well. 
These additional descriptors may also be constitutionally-based such as the V3 and V-I indices 
which denote vertices of valence three and fou r respectively. and L, which is defined as the 
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topological length of the two most separate points on the graph [Galvez et al.. 1994bl Other 
constitutional descriptors account for features such as number of rotatable bonds and molecular 
mass derivatives. and these have been included in models of drug solubi lity characteristics 
[Jorgensen & Duffy, 2002] and other pharmacokinel ic parameters [Herman & Veng-Pedersen, 
1994] with reasonable success. 
Table 1-2. Constitutional encoding ofbepridil (C2~H34N20). 
Stru cture 
,() H'CTO~~ 
CH, \.) V 
Encoding H C 0 N S aromatic carboxylic qUalemary ether 
ring acid ammonium 
Bin a ry 1 0 0 0 
Q ua nt ified 18 13 2 0 0 2 0 0 
1.5.2 Topologicnllndices 
Topological indices mathematically encode information regarding the structure of molecules which 
have been depicted as graphs. The molecular graph is comprised of venices which correspond to 
atoms and edges corresponding to the bonds between these atoms. Often they are sensitive to size. 
shape. branching. cyclicity and. to a certain extent, electronic characteristics of molecules 
[Todeschini & Consonni. 2oo0}. Subgraphs are defined as two or more venices connected by a 
bond or common path. Subgraphs may include branched and cyclic structures. and can have up to as 
many venices as the entire molecular graph. 
The seminal contribution to the field of topological indices was the introduction of the Wiener 
index. The Wiener index is defined as the sum over all bonds of the product of the number of 
vertices on each side of the bond [Wiener. 1947]. This index has been used extensively in the 
construction of QSPRs and QSARs for structurally related [Zakarya et al .. 1991J and unrelated 
[Gal vez et al .. 1995J drugs. Performance has also been improved following modification of the 
single Weiner number to extended Weiner indices (Estrada. 19991. 
The next significant topological index to be developed was the branching index proposed for a 
series of alkanes [Randic, 1975]. The Randic branching index. a precursor of the Kier and Hall 
connectivity indices. has led to successful elucidation of numerous topological-based QSARs and 
QSPRs. However. the physicochemical significance of the Randic index was undefined for decades 
after its inception. Only recently has the link between these theoretical numbers and their relation to 
physical chemistry been revealed. Research demonstrating that the branching corresponds to the 
relative area of accessibility of a molecule has established that physical meaning can be extracted 
from theoretical descriptors [Estrada. 2002a}. 
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1.5.2.1 Connectivity Illdices 
Kier and Hall connectivity indices. also called chi (X) indices, were developed to calculate zero- and 
higher-order connectivity descriptors [Kier & Hall. 1977]. Numerous correlations between 
connectiv ity indices and both physicochemical properties [Reinhard & Drefahl. 1999] and 
biological activity [Kier & Hal!, 1986a] of drugs have been identified. mostly for structurally 
related compounds. 
These descriptors are theoretical in nature so the absolute meaning of each index is not easily 
described. However. since the method of calculation is well defined then certain indices may 
describe some specific features of a molecule (Table 1-3). Moreover, recent work for both 
structurally related and struct urally unrelated compounds has revealed the relationship between 
connectivity indices and molecular accessibility area [Estrada, 2002b]. Since molecular accessibility 
area is importam in chemical interactions then such a relationship demonstrates the relevance of 
topological indices in drug models, Connectivity indices mathematically describe molecular 
structure by encoding branching and cyclicity (non valence X) and heteroatom influence (valence X). 
They cannot. however, encode absolutely eve!), single structural feature of a molecule. For 
example. structures exhibit ing cis/trails isomerism and atomic chirality are not differentiated from 
one another by connectivity indices (Cao & Yuan. 2002]. Modification of connectivity indices has 
been proposed to account for such shortcomings [8asak et al.. 2000cJ. although simple connect ivity 
indices still remain popular in the broader scientific and industrial community. Details of the 
methods of calcu lation of connectivity indices are given in Section 4.2.2.1 . 
Ta ble 1-3. Information content of Kier and Hall connectivity indices [Kier, 1987]. 
Index 
' X 
'X 
, " X 
'x 
' No 
, 
X, 
'N< 
, . 
X", 
Information Content 
General features about atoms or points, including molecular volume. molar refractivity. 
density and magnetic susceptibility 
Number of atoms in the molecule, and related surface area and volumes. relative 
branching in structural isomers 
Molar refractivity, orbital electronegativity. molecular polarity, structural differences 
for six-membered rings 
Information about branching (three-atom fragments) 
Flexibility. conformational gauche-anti rearrangements 
Branching, density, multiplicity of"cross-road" atoms 
Structural description of substituted aromatic rings and information about the 
orientation of ring substituents 
Number of benzene ring substituents. the substitution pattern. length of the substituents 
up to three bond lengths, and heteroatom type of substituent (in conjunction with 4X,pc) 
The application of simple connectivity indices extends from lead compound searching [Casaban-
Ros et aI. , 1999] to QSARs and QSPkRs [Cercos del Pozo et al.. 1996]. Studies have been 
performed for structurally diverse drugs and individual indexes have been shown 10 be important 
for different activity and property parameters. Linear combination of connectivity indices, for 
example differences and quotients. can describe features such as number and nature ofheteroatoms. 
as well as inductive and mesomeric effects of molecules (Galvez et aI., 1994bJ. Hence, they provide 
a valuable adjunct to the information presented by connectivity alone and have been utilised 
successfully in structure-pharmacokinetic studies [Rose el al .. 2002]. 
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1.5.2.2 Electrot()p%gictl/ Jlldices 
Biological and chemical properties of molecules rely on both their structural and electronic 
attributes. Since topological indices such as the Wiener index and connectivity indices describe 
fea tures of a molecule principally from a structural perspective. topological charge indices were 
developed to explicitly describe the charge distribution characteristics in a molecule. 
The topological charge indices. Gk. encode the 10lal charge transfer between atoms in a molecule at 
a distance Ie from one another [Galvez el al" 1994a]. Thus, Gk indices are related to the dipole 
moment of a molecule. and can be of the order one 10 L. For acyclic compounds, Jit indices 
represent the mean value for the charge transfer across the molecule and are a modification of the 
corresponding G. indices. Details regarding calcu lation are given in Section 4.2.2.1. Although 
originally defined for acyclic alkanes, G. and J. have been used to model physicochemical 
propenies and biological acti vity of both structurally sim ilar and structurally diverse drugs, 
including cyclic compounds [Galvez et al .. I 994b; Galvez et aI. , 1995]. 
Electrotopological state indices, S" are based on the "intrinsic state" of atoms which is related to 
their valence state [Kier & Hall. 1990]. Intrinsic states have been defined for 39 d ifferent atom 
vatence states. which allow calculation for a wide range of molecular structures. In addition to 
structure·activity relationships. these electrotopological state or E-state indices have successfully 
been correlated with aqueous solubi lity [Huuskonen et al.. 1998]. blood-brain panilioning in 
combination with connectivity indices [Rose et aJ.. 2002]. and volume of distr ibution [Ghafourian et 
.1..20061· 
1.5.3 Quantum Chemical Numbers 
Typical quantum chemical numbers include energies of the lowest unoccupied molecular orbital 
(LUMO) and highest occupied molecular orbital (HOMO). dipole moment. dielectric energy. steric 
energy. 10lal energy. minimum energy. heat of formation. and electron affinity. Quantum chemical 
calculations rely on the 3D structure of molecules. Descriptors obtained in this manner are therefore 
sensi tive to conformational changes of a compound. Molecules typically undergo an energy 
minimisation routine ill silico in order to obtain the anticipated h' vivo 3D conformation. Even 
though quantum chemical numbers provide information representing absolute thermodynamic and 
electronic propenies for a molecule, these values may not apply to an in vivo situation where the 
conformation of the molecule differs from the proposed ill silico representation. Thus, caution 
shou ld be exercised when interpreting the meaning of quantum chemical numbers at a detailed 
level. They have. however, provided useful information on a broader scale from complexation 
[Estrada et a1.. 2001] to strtlcture-pharmacoldnetic studies [Ekins & Obach. 2000]. Moreover. it is 
easier to interpret the physicochemical meaning of quantum chemical numbers than it is to interpret 
other topological indices. 
Several studies have demonstrated the imponance of quantum chemical considerations in the 
intestinal penneabitity of structurally diverse compounds. One study examined 18 theoretical and 
quantum chemical descriptors using principal component analysis [Winiwaner et al.. 1998]. It was 
established [hat the information content in those principal components was sumcient to indicate a 
relat ionship between structure and permeability. It was found. however, that qwmtum chemical 
numbers did not rank as highly as other theoretical partitioning and solubi lity descriptors, and that 
better models were constructed without the quantum chemical numbers. 
Another study generated 42 theoretical descriptors for 254 drugs. and reduced the number to 12 in 
the final model. Of Ihose 12, five were quantum chemical numbers. and their innuence on 
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membrane penetration was quantified [AgalOnovic-Kustrin el al., 2001]. It was found that the 
significance of dielectric energy was more than double the next most important descriptor. Alone. 
quantum chemical numbers have been correlated with metabolism properties in rats [Cupid et a1.. 
1999]. The urinary excretion of a series 22 of benzoic acid analogues and thei r metabolites was 
modeled using linear regression. Several models were developed and reasonable prediction 
correlations were achieved. Owing to the complexity of metabolic pathways, development of 
structure-metabolism relationships is considerably difficult. It has been demonstrated that 
relationships can be developed for structurally related compounds. Therefore. the next challenge 
would be to extend models to include large numbers of structurally diverse compounds. 
1.5.4 Solubility and Partitioning 
As descri bed earlier, solubility and lipophilicity are vital elements in detenn ining the entry of drugs 
into the body via the oral route. Solubility characteristics can limit absorption from the Gl tract 
while oi l/water partitioning can affect drug distribution and binding 10 proteins. Many studies have 
correlated physicochemical as well as theoretical descriptors with experimental solubi lity and 
oil/water partitioning, and this is dealt with in Section ! .6.1. Calculated solubility and solubility-
related parameters are often related to the ionic and electronic characteristics of a molecule. One 
scheme represents solubility as a combi nation of dispersion, polarity and hydrogen bonding values 
to give a vector in 3D space which describes a "radius of interaction"' of a mo[ecule [Hansen. 1967]. 
[n contrast, calculation of partition coefficients is performed according to an additivity method. One 
approach for generation of calculated log P (clog P) sums the contribution to lipophilicity at an 
atomic level [Viswanadhan et al., 1989], while another employs contribution of functional groups to 
lipophilicity [Hansch. 1979}. There have been improvements suggested for both of these methods 
[Wildman & Crippen, 1999]. Nevertheless, clog P values obtained using either method have been 
validated using large numbers of compounds. and have proven useful in a broad range of structure-
act ivity/-property relationship appl ications [Lipinski et al., 200 I]. 
Understandably, studies exami ning intestinal permeability have found clog P to be an important 
descriptor. One study developed a number of models using different combinations of descriptors 
and found clog P to have large regression coefficients in several models [Winiwarter et al.. 1998]. 
Another ANN study using numerous theoretical descriptors determined clog P to have the greatest 
effect on the model [Agatonovic-Kustrin et al.. 2001]. The importance of clog P as in indicator of 
bioavailabi lity is also apparent from its inclusion in the Rule of Five [Lipinski et al .. 1997] (Section 
1.2.3) which is utilised widely in the drug development industry. 
1.5.5 Other Descriptors 
A multitude of other descriptors exist. some with easily identifiable meaning and others more 
abstract. Geometrical and bulk descriptors provide information regarding the 3D characteristics of a 
molecule. Calculated surface area. molar volume. and solvent accessible area all depend on the 
particular conformation adopted by a molecule ill silica. Hence. a suitable approach to detennine 
the 3D conformation of molecules must be employed to ensure validity of descriptors. These 
descriptors have not been used to a great extent in the literature for QSPk R analyses due to their 
dependence on molecular conformation and their lack of relevance to QSAR studies. QSPkRs rely 
on the abili ty of drug molecules to be absorbed and excreted which in turn depends on the size and 
shape of molecules. For example, size and shape characteristics can affect glomerular filtration. and 
they have been shown to affect the rate of membrane permeabili ty [Ghafourian & Fooladi , 2001]. 
Accordingly. geometric and bulk parameters are potentia!ly more useful for QSPkRs than QSARs. 
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Many topological descriptors rely in a specific representation ofa molecule as a graph or matrix. By 
changing the manner of representation, different descriptors encode for diverse theoretical 
characteristics of a molecule. It would be prudent. therefore. to incl ude numerous theoretical 
descriptors in the initial stages of model construction to adequately represent the multidimensional 
nature of a molecule and its potential interactions in physiolocial systems. 
1.6 Structure-Pharmacokinetic Relationships 
The ANN modeling technique utilised in the present research has been employed extensively in 
QSAR analyses over the lasl decade. There are many examples of activity. toxicity. and 
carcinogenicity studies in the li terature, however, the reader is di rected 10 the following references 
[Maddalena. 1996; Basak et a!.. 2000b; Buchwald & Bodor. 2002; Greene. 2002; Mager. 2006] 10 
avoid unnecessary d iscussion in this work. Other structure-property applications in pharmaceutics 
include formulation optimisation [Takayama et al.. 1999], parti tion coefficient prediction 
[Huuskonen et a l .. 2000b], and infrared spectra analysis. and chromatographic re tention modeling 
[Agatonovic-Kustrin & Beresford, 2000J. 
Early QSPkR model development relied on regression equations to correlate physicochemical 
properties of drug molecules with pharmacokinetics [Haj- Yehia & Bialer. 1989J. It was suggested 
that QSPkRs should be confined to structurally similar compounds in order to avoid the risk of 
encountering discontinuities in pharmacoki netic propenies. For example. log P for a set of 
sulfonam ides can determine plasma protein bindi ng but may not effectively represent protein 
binding of penicill ins. It was also proposed that models explaining only 60% of the variance for a 
particular pharmacokinelic parameter could be deemed adequate for the purpose of providing useful 
information about a particular congeneric series of drugs [Seydel & Schaper. 198 I]. Consideri ng 
the high stakes rest ing on successful drugs reaching the market as well as the cost of development 
of apparent failures . such a poor figure may now no longer be acceptable. 
Recently. more functional QS PkRs have been developed to model the pharmacokinetics of 
structurally diverse sets of drug data [Herman & Veng-Pedersen. 1994]. Although still employing 
linear regression techniques, these QSPk R studies demonstrated that predict ion of pharmacokinetic 
parameters was not necessarily limited \0 congeneric series of compounds. The use of 
physicochemical descriptors was the fi rst logical step due to their general acceptance in other 
QSA R and QSPR studies. Theoretical descriptors have also been considered in combination with 
physicochemical descriptors 10 account for diffusion characteristics which may influence 
pharmacokinetics [Herman & Veng-Pedersen. 1994). Finally. QSPkRs conSlTucted solely from 
theoretical descriptors have shown promise in locating biologically active compounds amid 
structurally diverse drugs and also in modeling distribution half life [Galvez et al .. 1996]. The 
regression techniques employed allowed simple models to be constructed. Ho\\·ever. it has been the 
use of more robust soft computing methods that has increased over time instead. 
1.6.1 Absoq}tioll 
Absorption at the sile of administration can influence drug bioavaiJability. Drugs administered 
intravenously do not undergo absorption processes, whereas other routes of administration generally 
require absorption to occur before a drug is available to the body. For orally-delivered formulations 
in particular (inc luding tablets and capsules), disin:egration. deaggregation. dissolution. absorption. 
and first-pass metabolism all contribute to the bioavailabi lity ofa drug. For a drug to be absorbed it 
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must first go into solution in order 10 cross biological membranes (Figure 1-4). For an orally-
delivered drug that has poor dissolution characteristics Ihe lime spent al absorption siles in the Gl 
tract may be insufficient for complete absorption 10 occur. In such a case residence time in the OJ 
tracl can be increased by slowing intestinal motility, however. bioavailability may still be limited by 
the drug solubility. 
Solid 
dosage 
form 
± disintegration 
± deaggregation )0 Drug 
dissolution)o Drug, in 
solutIon tra~:f~b~~~SS .. 
Absorbed 
drug in 
blood 
Figure 1-4. Sequence of events in drug absorption from solid oral dosage forms. 
One study examining three different datasets containing congeneric drug compounds aimed 10 
predict aqueous solubility using topological indices [Huuskonen et al.. 1997]. Solubility data was 
taken from the literature and cluster analysis was used to select an uncorrelated subset of five 
descriptors from the many descriptors that were gencrated. Models were subjected to the leave-one-
out (LOO) cross-validation testing to overcome over-training and also as an indication of predictive 
ability. Even though it does nOl provide a true measure of the predictive ability of a model LOO 
cross-validation is useful when the size of dataselS is limited. 
The results obtained demonstrated a number of important points. First, successful models were able 
to be constructed using simple calculated descriptors rather than from experimental data. Second. 
ANN models were found to be more robustlhan regression models of similar data and. third, some 
models required more than a single class of topological indices to enable reasonable prediction. In 
further developments. other topological indices have been used to construct models for drugs not 
part of a congeneric series. Since 3D structure is important in dissolution. descriptors encoding 
geometrical properties of a molecule as well as charge distribution have been correlated with 
aqueous solubility using both regression and ANN tethniques [Bodor et al.. 1991J. Since 3D 
information was required, energy minimisation routines were appl ied to drug structures to arr ive at 
appropriate conformations. True pred ictive ability was tested with an independent set of compounds 
and in most cases ANN models were found \0 be superior to regression modcls. The requirement to 
fully represent all substituents and structure permutations in the training set was apparenl with the 
finding of one outlier in the independent test sct which was not completely represemed in the 
training set. 
Other recent structure-solubili ty relationship studies have examined even more diverse drug 
datasets inclusive of compounds containing heterocyclic rings and mUltiple functional groups 
[Huuskonen et al.. 1998]. Large numbers of topological indices were generated. and sensitivity-
based pruning was applied to determine the most in nuential descriptors. Although the approach and 
resul ts were sound. applicability to a broader range of chem ical structures was restricted because of 
the limited structure representation in the original dataset. By increasing the size of the drug dataset. 
a greater variation in structure was represented. In addition. larger tcst scts were able to be 
employed to provide a beller estimate of predict ive ability of the model (Huuskoncn et al. , 2000a). 
Predictive results were improved but since only 20 electrotopological indices were employed the 
model was nOI able to be explained in physicaltcrms. 
Once in solution. the penetration of drug molecules across a membrane is the next step in 
absorption. One study modeled passive drug absorption in rat intestine for a small, struclurally 
diverse series of drugs using immobilised anificial membranes [Genty et aI., 2001], Consistent 
experimental Olclhods and condilions were ensured by performing in viTro experiments to determine 
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the input descriptors and target absorption values rather than collecting data from the literature. 
However. the resources required for such experiments were greater than needed for pure in silico 
modeling. At any rate, im proved predictive ability was obtained wilh the addition of a theoretical 
descriptor. 
Similarly, a combination of experimental and theoretical descriptors has also been used for 
prediction of human intestinal absorption of drugs [Winiwarter et al.. 1998J. The limitation of 
experimentally determining log P as a descriptor variable meant that only a small training set of 
compounds was used. The variation in structure was assumed 10 be representative of a large number 
of current drugs so prediction or the absorption of independent compounds was reasonable. A larger 
study using ANNs developed cross-validated models which were then tested with independent 
compounds [Wessel et al.. 1998]. Only theoretical descriptors were utilised in model construction. 
with absorption data taken from the literature. A number of methods were used to reduce the 162 
descriptor set to the final 6, al l of which eliminated rather than combined descriptors. Since many of 
the descriptors were linearly correlated, differel11 final combinations could be found using genetic 
algorithm selection. Use of cross-validation and independent test sets reduced the training set to 76 
compounds for which the model constructed could not be considered a broadly applicable 
predictive tool. The model did. however. clearly differentiate between drugs with high and low 
absorption values. 
A similar study approached prediction of intestinal absorption with a view to explaining the 
meaning of theoretical descriptors in the QSPkR model [Agatonovic-Kustrin et aJ.. 200 1]. This was 
achieved using a radial-basis function ANN and by generation of descriptors encoding atomistic to 
3D holistic properties. There were 15 descriptors in the optimum model representing a combination 
of constitutional, hydrophobic, electronic and steric properties. In addition 10 qualitatively 
indicating absorption characteristics. predictive results were quantitatively more accurate than in the 
original study. It was emphasised that stud ies based on literature data should be selective to avoid 
accumulation of poor or inappropriate data. 
A number of struclUre-bioavailability relationships have been established using theoretical 
descriptors. One model constructed for 232 commercial drugs classified compounds into four 
classes according to their predicted bioavailability [Yoshida & Topliss. 2000]. Another QSPkR for 
59 1 compounds developed using stepwise regression demonstrated that predictions were more 
accurate than those achieved using Rule of Five [Andrews el al.. 2000]. Both studies included 
com pounds spanni ng a broad range of chemical st ructures which made them substantially more 
valuable than models conSlTucted sim ply from structurally related compounds. Prediction of 
bioavailabi li ty, as opposed to broad classification. was performed in the latter and not the former, 
whereas model tes ting using independent compounds was performed in the former and not the 
latter. To be ofmosl use in drug development. models should ultimately contain aspects of both and 
be developed to quantitatively predict the bioavailability of unknown compounds. 
1.6.2 Distr ibution 
Once a drug is absorbed into the systemic circulation its subsequent reversible transfer to 
extravascular fluids and tissues is termed dis tribmion (Figure 1-5). 
Distribut ion is usually a more rapid process than elimination such that distribution is generally 
complete while there is still an appreciable amount of drug in the body. Drugs are onen bound to 
proteins in the plasma such as albumin or in tissues. Some drugs distribute preferentially to tissues 
such as muscle. broin. skin. and fal. or to organs involved in elimination such as the kidney or liver. 
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Figure 1·5. Schematic diagram ora) absorption. b) distribution, and c) elimination in humans 
(adapted from [Gibaldi. 1984b]). 
The partitioning of a drug between tissue and blood is an important phannacokinetic property 
describing the d istribution of thaI drug in the body under steady-state conditions. Extent of 
partitioning is given by the partition coefficient. P, b. is defined as follows (Equation 1-2): 
C,j 
P. . = je. Eq uation 1-2 
where C, is the concentration of drug in the tissue of interest and Cb is the drug concentration in the 
blood {Shargel & Yu. 1999J. Depending on the characteristics of the drug and availability of plasma 
pharmacokinetic data. it may sometimes be more appropriate to use the ti ssue/pl asma partition 
coefficient. p/:p . 
Several studies have constructed models to predict P, p from experimental oil/water partitioni ng and 
protein bind ing measuremenls {Poulin & Theil. 2000; Poulin et aI., 200lJ. Models were applied to 
structurally unrelated compounds for a range of tissues in rabbit. rat. mouse and human. The 
mechanistic nature of the models allowed deductions regarding the efTect of lipophilicity on 
partitioning. as well as causal factors for distribution to particular tissues. Progress was made 
towards the goal of developing ill silico prediction tools from literature data. however the drug 
dataset size limited the general applicability of these models to more diverse chemical entities. 
A comparison of mechanistic and ANN methodologies demonstrated that both techniques were able 
to provide acceptable models for prediction of log P and tissue-to-unbound plasma concentrations 
for series of analogues [Nestorov el al. , 1999]. Physicochemical data was determined 
experimentally for the construction of both models. however, suitable literature data could have 
been used instead. Both ANN and PBPK models were constructed using the same descriptive data. 
The ANN model provided similarly accurate predictions as the PBPK model did but did not supply 
any mechanistic information. Should predictions only and not mechanistic information be required. 
Ihe ANN model could be considered to have equal perfonnance to the PBPK model. Neither of the 
models was deemed superior and it was suggested that the alternative technique should not be 
discarded in favour oflhe other. Instead. they should be used to complement onc another. 
In another structure-distribution study the distribution of a broad range of drugs into the brain was 
modeled [Basak ct al.. 1996]. Input descriptors were topological and E-state indices and the targct 
output parametcr was the blood/brain partition coefficient. Variables were manually pruned initially 
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and then subjected 10 statist ical analysis to develop regression equations 10 predict the blood/brain 
partition coeffic ient. In addition to demonstrating their importance in determining tissue 
distribution. the optimum Ihree·descriplor model allowed Ihe relationship between topological 
indices and the physicochemical parameters of hydrogen bonding. aromalicilY. and molecu lar 
branching 10 be examined. 
The apparent volume of distribution does not have a true physiological meaning but represents the 
theoretical volume into which the drug is distributed. Volume of distribution at steady state can be 
defined as (Equation 1·3): 
A,I 
V" = Ie, Eq ua tion 1-3 
where Ab is the amount of drug in the body and C, is the concentration of drug in the plasma. High 
volumes of distribution indicate the preference of a drug to reside in tissues outside the plasma 
includi ng erythrocytes and extravascular tissues. Conversely. low volumes of distribution indicate 
that a drug is confined mainly to the plasma [Rowland & Tozer, 1995dJ. Apparent volume of 
dist ribution. or more specifically the volume of distribution of the unbound fraction. can provide 
useful clinical information since it is generally considered that the unbound fraction is responsible 
for the phannacological action a of drug. 
Prediction of volume o f distribution has been performed using ANNs for 45 structurally unrelated 
drugs [Ritschel ct a1.. 1995]. Physicochemical parameters of compounds. allometric data. and 
theoretical descriptors were used as model inputs. Validation was performed using a leave-I/-out 
method. Rather than selecting an optim um set of descriptors. various combinations were evaluated 
fo r predictive ability. It was found that models which included log P. protein binding. and 
allometric data performed the best. although no detailed analysis of descriptor significance was 
perfonned. 
A similar study constructed various QSPkR models for a small series of Il-adrenoceptor antagonists 
[Gobburu & Shelver. 1995]. Volume of distribution of the total drug at steady state as well as the 
volume of distribution of the unbound fraction at steady state were modeled using ANNs and 
physicochemical descriptors taken from the li terature. Only one neuron in the hidden layer of the 
ANN was required to model the volume o f d istr ibution of the unbound fraction. Th is indicated a 
linear relationship between the input and output spaces. Fraction bound to plasma proteins was also 
modeled and req uired a relatively large number of hidden neurons. Since ANN architecture is 
generally representative of the complexi ty of the parameter being modeled it was surprising to see 
the fraction bound requiring five hidden neurons when compared with the single hidden neuron 
model for volume of distribution of the unbound fraction. Nevertheless. ANN results were an 
improvement on those obtained using multilinear regression for both training. LOO cross-
validation. and testing set predictions. 
1.6.3 Metabolism and Excretion 
Elimination of drugs for the body occurs via the processes of metabolism and excretion (Figure t-
6). 
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fi gure 1-6. Drug elimination depicted schematically, showing processes of a) metabolism and b) 
excretion (adapted from [Rowland & Tozer, J995bJ). 
Drug metabolism , or biotransformation, is the chemical conversion of the parent species into one of 
a number of metabolites. Drugs are excreted from the body as either the parent compound or as one 
of the metabolites. Excretion is primarily via the renal pathway via the urine, and also through the 
hepatobiliary route via the faeces. For volatile compounds it may be through the breath. and 
occasionally drugs are also excreted in the sweat. These are mainly Phase I reduction. oxidation. or 
hydrolysis reactions and/or Phase II conjugation reactions. Enzymes involved in metabolism are 
located predominantly in the liver. although o ther sites of enzymatic metabolism include the 
intestinal wall, kidney. lung, and skin. The major class involved in metabolism is the cytochrome 
P450 (CYP) enzyme superfamily, 
CY P isozymes often di splay structural specificity in metabolic reactions. Approaching metabolism 
from a modeling perspective is greatly challenging due to the complexity of the metabolic system in 
its entirety. Different drug classes can be metabolised by different enzyme classes, and the same is 
often true even for structurally related compou nds. Moreover, it is not uncommon for a drug to 
metabolised by si multaneous and competing enzymatic pathways. The extent of such metabolism 
depends on the individual rate constants of the competing pathways. To further compl icate matters, 
expression and morphology of metabolic enzymes can show large variations across ethnic groups. 
One approach in structure-metabolism relationship modeling has been to characteri se mol ecules or 
st ructural motifs likely to interact with one specific enzyme [Mlinsek et aI., 2001]. In doing so, the 
problem is simplified to dealing with a known target structure composed of one or more identifiable 
active si tes. Thus, characterisation of the structural c haracteristics of theoretical ligands which 
affect binding is more easily perfonned. A study examining flavonoid derivatives made use of 
quantum chemical descriptors to model the inhibition of CYP IA2 [Moon et aI., 2000]. 3D 
conformation of ligands is crucial for enzyme binding so all structures were presented as energy-
minimised conformers. Both multilinear regression and ANN models were constructed, with one 
ANN model making use of the same descriptors as the multilinear regression model. Direct 
comparison of predictive ability of each technique was thus possible, and since nonlinear 
relationships were assumed in fiavonoid-CYP IA2 binding, the ANN provided superior results. 
Another subset of descriptors was determined for the ANN using sensi tivity-based pruning. This 
subset allowed more accurate predictions for the test set of compounds. Th is finding demonstrated 
the need for nonlinear methods of descriptor selection to be employed for non linear systems. 
A more difficult approach is to model the enzymatic biotransformation of drugs by possibly 
numerous potential enzyme species. Complexity can be reduced by examination of just a si ngle 
enzyme class instead of looking broadly at multiple enzyme classes. Carboxylic ester hydrolases 
catalyse the hydrolysis of a variety of ester-containing substances and are present in many human 
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tissues. They have broad substrate specificity towards esters and amides and it is known that a 
single drug compound can be hydrolysed by more than one par1icular enzyme. The ill vitro 
metabolism of a number of structurally unrelated compounds was modeled based on structural 
characteristics [Buchwald & Bodor. 1999]. Conformation of 5ubSirate drugs was detennined by 
rigorous ill silica minimisat ion routines. From the minimised struclUres quantum chemical numbers. 
calculated log P descriptors, and a novel descriptor representing a theoretical sterk angle were 
generated. Even though traini ng results were acceptab le the prediction of enzymatic metabolism of 
independent test compou nds proved morc difficul t. The final models qualitatively differentiated 
between slowly and quickly metabolised substrates but quantitative predictions varied considerably 
from experimental values. An accurate predictive model was not expected. however. due to the size 
of the training dataset and complexity of enzymatic metabolism. 
In a different problem. classification of metabolic fate of drugs has been performed for structurally 
related com pounds. One study examined urinary excretion of glucuronide conjugates, glycine 
conjugates. and unchanged parent drug for 22 benzoic acid derivatives [Cupid et al., 1999]. 
Information regarding the metabolic enzymes was neither required nor explored since the study was 
not mechanistic by nature. Descriptors were calculated from structure and included quantum 
chemical numbers. geometrical descriptors. and partition coefficients. Predictive capability 
determined using a leave-2-out procedure indicated that structure-metabolism relationships were 
able to be modeled for the structurally-related compounds examined. 
1.6.3. 1 Cleurtlm:e 
Clearance is defined as the volume of blood cleared of drug per unit time. It is a function of both the 
intrinsic ability of eliminating organs such as the liver and kidney to excrete or metabolise a drug. 
and the blood flow rate to these organs (Figure 1-7). Clearance due to a single organ is given as the 
product of the blood fl ow \0 that organ and the extraction ratio (Equation 1-4): 
CL=Q.CA-Cr =Q·£R 
C, 
Equ ation 1-4 
where Q is the blood flow to the organ. CA is the concentration of drug in the arterial blood. CII is 
the concentration of drug in the venous blood, and ER is the extraction ratio. The extraction ralio is 
the mtio of the rate of el imination of a drug to the input rate of the drug to an organ. Th us, the 
higher the extraction rat io the more drug is eli mi mlted and the less passes through the eliminating 
organ inlact 
Eliminating 
organ 
or excretion 
Figure 1-7. Schematic diagram of drug elimi nation by a si ngle organ (adapted from [G ibaldi, 
1984,)). 
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Total clearance is a complex parameter since it combines elements of both metabolism and 
excretion. A sim pler parameter is renal clearance which mainly involves the processes of 
glomerular filtration and reabsorption. A comparison of models for renal and !lamenal clearance for 
a series of p-adrenoceptor antagonists gave sim ilar cross-val idation results for both (Gobburu & 
SheJver. 1995]. Even though th is was nOl the expected result it was most likely due to the small size 
of the dataset. When clearances of independent compounds were examined. only the prediction of 
renal clearance was acceptable whereas prediction ofnonrenal clearance was no\. 
In a related study a slightly larger dataset of more structurally diverse drugs was used to develop a 
model for in vil'o hepatic clearance [Schneider et a1.. 1999]. The aim was to com pare different 
modeling techniques to determine the feas ibility of developing structure-clearance relationsh ip 
models. A combination of allometric and ill vilro data were used as input variables. It was found 
that adequate cross-validated models could be achieved using in vilro data only. Even though the 
dataset was relatively small a variety of metabolic pathways were represented covering both Phase I 
and Phase JJ reactions. Nevertheless, more broadly applicable models would require much larger 
datasets to cover the large range of metabolic pathways and also to allow true predictive 
perfonnance using independent compounds to be assessed. 
A structure-clearance relation ship was developed in cor~unction with the structure-distribution 
relationship mentioned in Section 1.6.2 [Ritschel et ai., 1995]. The ANN model was novel in that 
two pharmacokinetic parameters. clearance and volume of distribution. were predicted 
simultaneollsly. Models were cross-validated but testing of independent drugs was not performed. 
Models were for the most part rather inaccurate. Moreover, quantitative structure-pharmacokinetic 
relationships were not examined. It was likely that the information content of the descriptors was 
inadequate to predict two complex pharmacokinetic parameters at once. 
I. 7 Summary Remarks 
A review of the literature revealed that predictive QSPkR modeling is a relatively undeveloped area 
in which there is ample scope for progress using newer soft comput ing techniques such as ANNs. A 
number of methodologies have been applied from both mechanistic and non-mechanistic 
approaches. Should solely predictive models be required then a non-mechanistic approach would 
seem appropriate. To aid in drug development, however. infonnation should be taken from the 
QSPkR models regarding the quantitative effects of structure on NCE phannacokinetics. QSPkRs 
that have been developed to date have mainly used physicochemical o r experimentally-deri ved 
parameters to construct models. Theoretica[ descriptors offer a quicker and more effective 
alternative. Each theoretical descriptor provides a certain amount of unique information. Modeling 
techniques need to be used that allow selection of the most appropriate set of descriptors for 
optimum predictive capabilities. Moreover, a combination of descriptors should be used initially to 
encode as much of the multidimensional nature of a chemical st ructure as possible. 
ANNs have thus far only been used to a small e.xlent in developing QSPkRs. They are a robust 
model ing tool and have certain speed and nonlinearity advantages where other methods do no\. 
Construction of ANN-based QSPkRs should be demonstrated to be effective in si mple systems first 
such as for structurally related sets of compounds, and then extended 10 include larger numbers of 
structurally diverse compounds. All models should be validated with an appropriate technique to 
ensure adequate predictive capability. [n the literature to date most studies have addressed some of 
these issues but not all have to any great extent. The studies presented in this moograph validates 
Ihe applicability of the present technique for both small and large sets of data. and in doing so 
, I 
/lIIrodllcliOI1 
addresses the issue of congeneric and structurally diverse drug datasets. The modeling described 
takes its basis from conventional QSPkR modeling published using both physicochemical and 
theoretical descriptors. A ll models were appropriately val idated to ensure reliability in contrast to 
some earlier st udies. In utilising ANNs and theoretical descriptors these studics have advanced the 
field of QSPkR modeling with a view to aiding the drug discovery and developmcnt process in the 
early stages. 
32 
